мȸ ǥ ʷ

ǥ : ȣ - 530027   201 
Effects of Combined Therapy with Ezetimibe Plus Simvastatin After Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model
대전성모병원1, 전남대학교병원심장센터2
조정선1, 홍영준2, 정명호2, 김성수2, 김현국2, 고점석2, 이민구2, 박근호2, 심두선2, 윤남식2, 윤현주2, 김계훈2, 박형욱2, 김주한2, 안영근2, 조정관2, 박종춘2, 강정채2
BACKGROUND: In drug-eluting stent (DES) era, main concern about the DES was divided to ISR by neointimal hyperplasia and late stent thrombosis by delayed arterial healing. In this aspect, statin could be expected to have therapeutic potential in both aspects. Previous studies have shown that, in addition to the favorable effects on lipid levels, combined therapy with ezetimibe plus simvastatin produced significant reductions in C-reactive protein relative to statin monotherapy. OBJECTIVES: We examined the effects of ezetimibe/simvastatin on neointimal hyperplasia, inflammatory reaction, and endothelization for arterial healing after DES implantation in a porcine coronary restenosis model. METHODS: Pigs were randomized into two groups in which the coronary arteries (23 pigs, 28 coronaries in ezetimibe/simvastatin group, 15 coronaries in no ezetimibe/simvastatin group) had either a sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES). Stents were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries. Histopathologic analysis was assessed at 28 days after stenting. RESULTS: In neointima, most inflammatory cells were lymphohistiocytes. Lymphohistiocyte count was not different between two groups (337±227 cells vs. 443±366 cells, p=0.292). Furthermore, the percent of inflammatory cell among the total cell in neointima was not different between two groups (5.2±2.8% vs. 5.6±4.0%, p=0.73). Neointima area was significantly smaller (1.00±0.49 mm2 vs. 1.69±0.98 mm2, p=0.004) and percent area stenosis was significantly lower (23.3±10% vs. 39±19%, p=0.001) in ezetimibe/simvastatin group compared with control group. There was no significant differences in fibrin score (1.99±0.79 vs. 1.81±0.88, p=0.49), endothelial score (1.75±0.66 vs. 1.80±0.59, p=0.79), and the percent of endothelium covered lumen (43±21 % vs. 45±21 %, p=0.84) between two groups. CONCLUSIONS: Combined therapy with ezetimibe plus simvastatin may inhibit neointimal hyperplasia but does not inhibit inflammatory cell infiltration and arterial healing after DES implantation in a porcine coronary restenosis model.


[ư]


logo 학술대회일정 사전등록안내 초록등록안내 초록등록/관리 숙박 및 교통 안내 전시안내